Recipharm and LIDDS sign contract for production of prostate cancer treatment

Published: 15-Dec-2015

Recipharm will also invest SEK5m in a private placement and become LIDDS' third-largest shareholder


Recipharm and Swedish pharmaceutical firm LIDDS have signed an exclusive agreement regarding scale-up and commercial manufacture of Liproca Depot, LIDDS patented targeted treatment for prostate cancer.

The agreement will be an important component for the upcoming Phase IIb study which is planned to start in 2016.

Recipharm will also invest SEK5m (US$590m) in a private placement, thus becoming the third-largest shareholder of LIDDS.

'LIDDS’ technology platform is highly interesting as it potentially can be used for other, already approved therapies which may lead to shorter development time for new products,' said Carl-Johan Spak, EVP Development & Technology at Recipharm.

'We are looking forward to collaborating with LIDDS through contributing our technical expertise within production, and thus delivering a more gentle treatment for prostate cancer patients in the future.'

Monica Wallter, CEO of LIDDS, added: 'We are very pleased that the agreement with Recipharm has been signed, as it is an important part of the preparations for the next clinical study. This agreement will strengthen the attraction for out-licensing of Liproca Depot.'

You may also like